[3/3 Inhibitors of mTOR (sirolimus and everolimus)].
Chaumard
Natacha
N
Intrene en Pharmacie Hospitalière, CHU Besançon.
Limat
Samuel
S
Woronoff-Lemsi
Marie-Christine
MC
D004347:Drug Interactions; D016903:Drug Monitoring; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D018579:Patient Selection; D011494:Protein Kinases / Q000187:drug effects*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D058570:TOR Serine-Threonine Kinases; D014181:Transplantation Immunology
D007166:Immunosuppressive Agents; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus